Skye Bioscience, Inc.
SKYE
Rank in Stocks
#31472
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on... Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
Share Price
$0.69
Last synced: 2026-11-09
Market Cap
$3.06M
Change (1 day)
-30.32%
Change (1 year)
-52.74%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Skye Bioscience, Inc. (SKYE)
Category
Healthcare
Operating Margin for Skye Bioscience, Inc. (SKYE)
Operating Margin as of November 2026 TTM: 0.00%
According to Skye Bioscience, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Skye Bioscience, Inc. from 2012 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | -100.00% |
| 2013 | -2.13% | -108.40% |
| 2012 | 25.35% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Skye Bioscience, Inc.'s operating margin
What was Skye Bioscience, Inc.'s operating margin in 2025?
In 2025, Skye Bioscience, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Skye Bioscience, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Skye Bioscience, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2025 (0.00%).
How does Skye Bioscience, Inc.'s operating margin compare with similar companies?
Skye Bioscience, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.